Pharmaceuticals

Global Carbapenem-Based Antibiotics Market Projected to Reach $6.4 Billion by 2030 with 6.2% CAGR

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Carbapenem-Based Antibiotics Market By 2030 Starting From Its 2026 Size?

The carbapenem-based antibiotics market size has seen significant growth in recent years. It is anticipated to increase from $4.78 billion in 2025 to $5.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. The historical expansion of this market can be attributed to the increasing prevalence of bacterial infections, advancements in antibiotic formulations, growing awareness of nosocomial infections, a rising geriatric population, and the expansion of hospital networks.

The market for carbapenem-based antibiotics is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $6.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during this period is driven by several factors, including the rise of multidrug-resistant bacteria, advancements in combination therapies, improved healthcare accessibility in developing economies, the integration of precision medicine, and increased funding for new carbapenem derivatives. Key trends expected over the forecast horizon encompass growing antibiotic resistance, a rise in hospital-acquired infections, the expansion of hospital facilities, an increase in surgical interventions, and the need for antibiotics tailored for pediatric and geriatric patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Carbapenem-Based Antibiotics Market?

The rising occurrence of bacterial infections is anticipated to propel the expansion of the carbapenem-based antibiotics market moving forward. Bacterial infections are illnesses caused by bacteria, microscopic organisms capable of invading the body and leading to a variety of diseases and symptoms. Carbapenem-based antibiotics are employed to treat severe or multidrug-resistant bacterial infections, including those originating from gram-positive and gram-negative bacteria. For instance, in July 2024, a report from the Centers for Disease Control and Prevention, a US-based government agency, revealed that during 2023, 78% of all bacterial infections in the historic catchment area were diagnosed by CIDTs, with 46% exclusively diagnosed using CIDTs. Consequently, an elevated incidence of bacterial infections is driving the growth of the carbapenem-based antibiotics market.

Which Segment Categories Define The Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

What Major Market Trends Are Driving Changes In The Carbapenem-Based Antibiotics Market?

Major companies operating in the carbapenem-based antibiotics market are innovating financial and distribution models to sustain their market presence and support antibiotic stewardship. Subscription models aim to decouple revenue from volume sold, encouraging responsible use while ensuring profitability for pharmaceutical companies. For instance, in August 2024, the National Health Service (NHS), a UK-based government department, launched a pioneering subscription scheme in collaboration with the pharmaceutical sector to combat antimicrobial resistance (AMR). This innovative model allows drugmakers to receive fixed annual payments, up to $23.12 million (£20 million) per drug regardless of prescription volume, thus removing incentives for overuse. Valued at approximately £1.9 billion over 16 years, the scheme aims to stimulate the development of new antibiotics, including carbapenems, by ensuring financial viability for drug manufacturers. The NHS prioritizes products targeting critical pathogens identified by the World Health Organization, reinforcing its commitment to responsible antibiotic stewardship while fostering innovation in antibiotic development.

Who Are The Top Companies Competing In The Carbapenem-Based Antibiotics Market?

Major companies operating in the carbapenem-based antibiotics market are Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, Teva Pharmaceutical Industries Ltd., Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co. Ltd., ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Read the full carbapenem-based antibiotics market report here:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Which Regions Are Projected To Dominate The Carbapenem-Based Antibiotics Market In The Coming Years?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Carbapenem-Based Antibiotics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

Browse Through More Reports Similar to the Global Carbapenem-Based Antibiotics Market 2026, By The Business Research Company

Carbapenem Based Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Macrolide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795